Trials / Completed
CompletedNCT00114764
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce the time of severe neutropenia in patients receiving induction and consolidation myelosuppressive chemotherapy for de novo acute myeloid leukemia similar to filgrastim.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | filgrastim | Filgrastim given daily after induction chemotherapy |
| DRUG | pegfilgrastim | Pegfilgrastim given once after induction chemotherapy |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2004-04-01
- Completion
- 2004-08-01
- First posted
- 2005-06-20
- Last updated
- 2008-10-31
Source: ClinicalTrials.gov record NCT00114764. Inclusion in this directory is not an endorsement.